| 1 | Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer | 6.8 | 9 | Citations (PDF) |
| 2 | Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States | 2.8 | 8 | Citations (PDF) |
| 3 | Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer | 1.1 | 2 | Citations (PDF) |
| 4 | Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting | 2.3 | 5 | Citations (PDF) |
| 5 | Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors | 6.8 | 52 | Citations (PDF) |
| 6 | Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity | 4.1 | 15 | Citations (PDF) |
| 7 | Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress | 7.5 | 48 | Citations (PDF) |
| 8 | Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality | 2.1 | 11 | Citations (PDF) |
| 9 | The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer | 2.9 | 11 | Citations (PDF) |
| 10 | The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer | 6.8 | 51 | Citations (PDF) |
| 11 | Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different? | 1.5 | 4 | Citations (PDF) |
| 12 | Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer | 4.6 | 17 | Citations (PDF) |
| 13 | Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells | 6.8 | 37 | Citations (PDF) |
| 14 | Prostate‐specific antigen nadir and testosterone level at prostate‐specific antigen failure following radiation and androgen suppression therapy for unfavorable‐risk prostate cancer and the risk of all‐cause and prostate cancer–specific mortality | 4.0 | 4 | Citations (PDF) |
| 15 | Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors | 14.3 | 198 | Citations (PDF) |
| 16 | CD38 in Advanced Prostate Cancers | 2.1 | 38 | Citations (PDF) |
| 17 | Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer | 4.6 | 1 | Citations (PDF) |
| 18 | Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in
BRCA2
-altered Prostate Tumors | 6.8 | 20 | Citations (PDF) |
| 19 | Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer | 6.5 | 18 | Citations (PDF) |
| 20 | Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities | 2.1 | 61 | Citations (PDF) |
| 21 | Family history of prostate cancer and the incidence of ERG‐ and phosphatase and tensin homolog‐defined prostate cancer | 4.3 | 4 | Citations (PDF) |
| 22 | Significance of
BRCA2
and
RB1
Co-loss in Aggressive Prostate Cancer Progression | 6.8 | 111 | Citations (PDF) |
| 23 | Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer | 6.8 | 47 | Citations (PDF) |
| 24 | Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib | 6.8 | 20 | Citations (PDF) |
| 25 | Racial Differences in Genomic Profiling of Prostate Cancer | 34.5 | 123 | Citations (PDF) |
| 26 | Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell–Level PI3K Pathway Activation | 6.8 | 12 | Citations (PDF) |
| 27 | Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer | 6.8 | 178 | Citations (PDF) |
| 28 | Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer | 4.1 | 33 | Citations (PDF) |
| 29 | Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer | 2.8 | 6 | Citations (PDF) |
| 30 | Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | 16.9 | 54 | Citations (PDF) |
| 31 | Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions | 1.1 | 96 | Citations (PDF) |
| 32 | Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry | 4.0 | 106 | Citations (PDF) |
| 33 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 | 2.1 | 336 | Citations (PDF) |
| 34 | Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial | 4.0 | 36 | Citations (PDF) |
| 35 | Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics | 2.1 | 117 | Citations (PDF) |
| 36 | A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research | 2.7 | 13 | Citations (PDF) |
| 37 | Association of genetic variation of the six gene prognostic model for castration‐resistant prostate cancer with survival | 2.1 | 7 | Citations (PDF) |
| 38 | Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer | 4.0 | 65 | Citations (PDF) |
| 39 | High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program | 13.7 | 164 | Citations (PDF) |
| 40 | Treatment of Advanced Prostate Cancer | 18.7 | 648 | Citations (PDF) |
| 41 | Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy | 1.4 | 14 | Citations (PDF) |
| 42 | Methylation‐associated miR‐193b silencing activates master drivers of aggressive prostate cancer | 4.1 | 24 | Citations (PDF) |
| 43 | Genomic correlates of clinical outcome in advanced prostate cancer | 7.5 | 1,302 | Citations (PDF) |
| 44 | Aneuploidy drives lethal progression in prostate cancer | 7.5 | 127 | Citations (PDF) |
| 45 | Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types | 6.8 | 58 | Citations (PDF) |
| 46 | A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2) | 6.8 | 132 | Citations (PDF) |
| 47 | Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer | 1.1 | 23 | Citations (PDF) |
| 48 | Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications | 4.9 | 48 | Citations (PDF) |
| 49 | Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: A Randomized Clinical Trial | 4.6 | 161 | Citations (PDF) |
| 50 | Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer | 16.9 | 255 | Citations (PDF) |
| 51 | Impact of 5α‐reductase inhibitor and α‐blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality | 3.2 | 19 | Citations (PDF) |
| 52 | Treatment of Metastatic Prostate Cancer in 2018 | 14.3 | 18 | Citations (PDF) |
| 53 | Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade | 14.3 | 611 | Citations (PDF) |
| 54 | A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration‐resistant prostate cancer | 4.0 | 14 | Citations (PDF) |
| 55 | Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | 4.0 | 65 | Citations (PDF) |
| 56 | Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer | 1.1 | 14 | Citations (PDF) |
| 57 | Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology | 2.1 | 413 | Citations (PDF) |
| 58 | The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer | 4.2 | 56 | Citations (PDF) |
| 59 | Impact of time to testosterone rebound and comorbidity on the risk of cause‐specific mortality in men with unfavorable‐risk prostate cancer | 4.0 | 5 | Citations (PDF) |
| 60 | Current treatment strategies for advanced prostate cancer | 1.7 | 218 | Citations (PDF) |
| 61 | Low testosterone at first prostate‐specific antigen failure and assessment of risk of death in men with unfavorable‐risk prostate cancer treated on prospective clinical trials | 4.0 | 6 | Citations (PDF) |
| 62 | Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) | 2.1 | 189 | Citations (PDF) |
| 63 | The long tail of oncogenic drivers in prostate cancer | 25.2 | 791 | Citations (PDF) |
| 64 | Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer | 5.6 | 37 | Citations (PDF) |
| 65 | Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 | 2.1 | 530 | Citations (PDF) |
| 66 | Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone | 2.3 | 25 | Citations (PDF) |
| 67 | Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer | 0.8 | 31 | Citations (PDF) |
| 68 | Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA | 22.4 | 314 | Citations (PDF) |
| 69 | Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer | 0.3 | 51 | Citations (PDF) |
| 70 | Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer–Specific Mortality | 12.6 | 4 | Citations (PDF) |
| 71 | A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer | 2.1 | 5 | Citations (PDF) |
| 72 | Regular aspirin use and gene expression profiles in prostate cancer patients | 1.7 | 3 | Citations (PDF) |
| 73 | ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D | 10.6 | 77 | Citations (PDF) |
| 74 | Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy | 14.3 | 47 | Citations (PDF) |
| 75 | The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies | 4.0 | 7 | Citations (PDF) |
| 76 | Neoadjuvant Enzalutamide Prior to Prostatectomy | 6.8 | 123 | Citations (PDF) |
| 77 | Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6 | 3.8 | 41 | Citations (PDF) |
| 78 | The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer | 4.0 | 248 | Citations (PDF) |
| 79 | Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing | 16.5 | 483 | Citations (PDF) |
| 80 | Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer | 4.0 | 17 | Citations (PDF) |
| 81 | The impact of statin use on the efficacy of abiraterone acetate in patients with castration‐resistant prostate cancer | 2.1 | 26 | Citations (PDF) |
| 82 | Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer | 6.8 | 106 | Citations (PDF) |
| 83 | A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer | 6.8 | 31 | Citations (PDF) |
| 84 | Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer | 16.9 | 64 | Citations (PDF) |
| 85 | Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade | 4.0 | 65 | Citations (PDF) |
| 86 | Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer | 2.3 | 33 | Citations (PDF) |
| 87 | Institutional implementation of clinical tumor profiling on an unselected cancer population | 5.4 | 414 | Citations (PDF) |
| 88 | A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer | 2.1 | 0 | Citations (PDF) |
| 89 | Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis | 2.1 | 23 | Citations (PDF) |
| 90 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | 34.5 | 1,561 | Citations (PDF) |
| 91 | The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study | 4.8 | 32 | Citations (PDF) |
| 92 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma 2016, 4, | | 35 | Citations (PDF) |
| 93 | Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT | 1.1 | 57 | Citations (PDF) |
| 94 | Physical and emotional health information needs and preferences of long-term prostate cancer survivors | 2.1 | 26 | Citations (PDF) |
| 95 | Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer | 13.7 | 294 | Citations (PDF) |
| 96 | Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6 months of androgen deprivation therapy for men with unfavorable-risk prostate cancer | 0.4 | 0 | Citations (PDF) |
| 97 | Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression | 7.5 | 163 | Citations (PDF) |
| 98 | Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center | 2.3 | 11 | Citations (PDF) |
| 99 | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | 16.9 | 1,540 | Citations (PDF) |
| 100 | Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma | 2.3 | 38 | Citations (PDF) |
| 101 | Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer | 2.1 | 137 | Citations (PDF) |
| 102 | Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer | 14.3 | 96 | Citations (PDF) |
| 103 | Comparison of Prostate-Specific Membrane Antigen–Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer | 5.1 | 118 | Citations (PDF) |
| 104 | Cancer nanomedicine: progress, challenges and opportunities | 60.7 | 5,436 | Citations (PDF) |
| 105 | Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer | 4.0 | 9 | Citations (PDF) |
| 106 | Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015, 161, 1215-1228 | 33.6 | 3,277 | Citations (PDF) |
| 107 | Development and Clinical Validation of an
In Situ
Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer | 6.8 | 177 | Citations (PDF) |
| 108 | The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) | 4.6 | 58 | Citations (PDF) |
| 109 | Role of Androgen Deprivation Therapy in Early Salvage Radiation Among Patients With Prostate-Specific Antigen Level of 0.5 or Less | 2.3 | 19 | Citations (PDF) |
| 110 | Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome | 6.8 | 131 | Citations (PDF) |
| 111 | Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases | 2.9 | 47 | Citations (PDF) |
| 112 | A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer | 2.3 | 41 | Citations (PDF) |
| 113 | Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease | 4.2 | 67 | Citations (PDF) |
| 114 | GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis | 2.3 | 11 | Citations (PDF) |
| 115 | Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer | 14.3 | 133 | Citations (PDF) |
| 116 | Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer | 4.0 | 21 | Citations (PDF) |
| 117 | The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer | 5.0 | 60 | Citations (PDF) |
| 118 | DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors | 2.9 | 27 | Citations (PDF) |
| 119 | Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma | 1.0 | 41 | Citations (PDF) |
| 120 | Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer | 16.5 | 135 | Citations (PDF) |
| 121 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | 34.5 | 1,159 | Citations (PDF) |
| 122 | Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti–Prostate Cancer Activity | 6.8 | 15 | Citations (PDF) |
| 123 | The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis | 25.2 | 473 | Citations (PDF) |
| 124 | Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer | 3.1 | 16 | Citations (PDF) |
| 125 | Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations | 16.5 | 110 | Citations (PDF) |
| 126 | Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors | 6.8 | 165 | Citations (PDF) |
| 127 | Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them | 2.1 | 745 | Citations (PDF) |
| 128 | Identification of ALK Gene Alterations in Urothelial Carcinoma | 2.3 | 12 | Citations (PDF) |
| 129 | Somatic
ERCC2
Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma | 25.1 | 601 | Citations (PDF) |
| 130 | Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma | 6.8 | 80 | Citations (PDF) |
| 131 | A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T | 4.2 | 50 | Citations (PDF) |
| 132 | Suicidal ideation in prostate cancer survivors: Understanding the role of physical and psychological health outcomes | 4.0 | 56 | Citations (PDF) |
| 133 | FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder | 2.6 | 86 | Citations (PDF) |
| 134 | The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate‐risk disease | 4.0 | 49 | Citations (PDF) |
| 135 | Elevated insulin‐like growth factor binding protein‐1 (IGFBP‐1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival | 2.1 | 35 | Citations (PDF) |
| 136 | Percent positive biopsy cores and the risk of death from prostate cancer in men with unfavorable-risk prostate cancer | 0.4 | 0 | Citations (PDF) |
| 137 | Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening | 10.6 | 33 | Citations (PDF) |
| 138 | Effects of a gift certificate incentive and specialized delivery on prostate cancer survivors' response rate to a mailed survey: A randomized-controlled trial | 1.8 | 11 | Citations (PDF) |
| 139 | Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer | 29.8 | 528 | Citations (PDF) |
| 140 | Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and overall survival | 2.1 | 78 | Citations (PDF) |
| 141 | SPINK1 Protein Expression and Prostate Cancer Progression | 6.8 | 76 | Citations (PDF) |
| 142 | Development of Multinuclear Polymeric Nanoparticles as Robust Protein Nanocarriers | 1.4 | 10 | Citations (PDF) |
| 143 | Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG–Positive Prostate Cancer | 1.1 | 33 | Citations (PDF) |
| 144 | Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits | 1.3 | 53 | Citations (PDF) |
| 145 | Development of Multinuclear Polymeric Nanoparticles as Robust Protein Nanocarriers | 14.4 | 139 | Citations (PDF) |
| 146 | Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation | 7.5 | 380 | Citations (PDF) |
| 147 | Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib | 25.1 | 277 | Citations (PDF) |
| 148 | Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients | 2.5 | 78 | Citations (PDF) |
| 149 | Prostate Cancer, Version 2.2014 | 12.6 | 304 | Citations (PDF) |
| 150 | Role of diet in prostate cancer: the epigenetic link | 6.5 | 51 | Citations (PDF) |
| 151 | Identifying suicidal symptoms in prostate cancer survivors using brief self-report | 2.1 | 16 | Citations (PDF) |
| 152 | Early Detection of Prostate Cancer: AUA Guideline | 4.2 | 1,034 | Citations (PDF) |
| 153 | Observation Versus Initial Treatment for Men With Localized, Low-Risk Prostate Cancer | 9.6 | 112 | Citations (PDF) |
| 154 | Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial | 1.4 | 229 | Citations (PDF) |
| 155 | Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug | 7.5 | 335 | Citations (PDF) |
| 156 | Defining the optimal approach to the patient with postradiation prostate‐specific antigen recurrence using outcome data from a prospective randomized trial | 4.0 | 7 | Citations (PDF) |
| 157 | Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study | 27.4 | 52 | Citations (PDF) |
| 158 | Long-term Follow-up of a Phase II Trial of Chemotherapy Plus Hormone Therapy for Biochemical Relapse After Definitive Local Therapy for Prostate Cancer | 1.4 | 9 | Citations (PDF) |
| 159 | Synergistic Cytotoxicity of Irinotecan and Cisplatin in Dual-Drug Targeted Polymeric Nanoparticles | 3.0 | 70 | Citations (PDF) |
| 160 | Punctuated Evolution of Prostate Cancer Genomes | 33.6 | 1,265 | Citations (PDF) |
| 161 | Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low‐risk, localized prostate cancer | 2.1 | 230 | Citations (PDF) |
| 162 | Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG | 4.6 | 87 | Citations (PDF) |
| 163 | A Single Nucleotide Polymorphism in Inflammatory Gene
RNASEL
Predicts Outcome after Radiation Therapy for Localized Prostate Cancer | 6.8 | 22 | Citations (PDF) |
| 164 | Clinical predictors of survival in men with castration‐resistant prostate cancer | 4.0 | 36 | Citations (PDF) |
| 165 | The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer | 4.0 | 17 | Citations (PDF) |
| 166 | New Developments in the Management of Prostate Cancer | 12.6 | 17 | Citations (PDF) |
| 167 | MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A | 6.5 | 142 | Citations (PDF) |
| 168 | Neuroepithelial Tumor Arising in a Testicular Teratoma With Retroperitoneal Metastasis | 16.9 | 1 | Citations (PDF) |
| 169 | Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer | 4.6 | 33 | Citations (PDF) |
| 170 | Genetic and functional analyses implicate the
NUDT11
,
HNF1B
, and
SLC22A3
genes in prostate cancer pathogenesis | 7.5 | 109 | Citations (PDF) |
| 171 | Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer | 16.9 | 171 | Citations (PDF) |
| 172 | Prostate-Specific Antigen Test for Prostate Cancer Screening: American Society of Clinical Oncology Provisional Clinical Opinion | 2.9 | 10 | Citations (PDF) |
| 173 | New Agents in Metastatic Prostate Cancer | 12.6 | 13 | Citations (PDF) |
| 174 | Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines | 12.6 | 215 | Citations (PDF) |
| 175 | Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer | 3.2 | 75 | Citations (PDF) |
| 176 | Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials | 27.4 | 81 | Citations (PDF) |
| 177 | BRAF Mutations in Metanephric Adenoma of the Kidney | 2.1 | 114 | Citations (PDF) |
| 178 | Influence of Androgen Deprivation Therapy on All-Cause Mortality in Men With High-Risk Prostate Cancer and a History of Congestive Heart Failure or Myocardial Infarction | 1.5 | 71 | Citations (PDF) |
| 179 | Posttreatment Prostate Specific Antigen Nadir Predicts Prostate Cancer Specific and All Cause Mortality | 4.2 | 23 | Citations (PDF) |
| 180 | Integration of immunotherapy into the management of advanced prostate cancer | 1.8 | 11 | Citations (PDF) |
| 181 | Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion | 16.9 | 131 | Citations (PDF) |
| 182 | The
TMPRSS2:ERG
Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis | 1.1 | 301 | Citations (PDF) |
| 183 | Immunotherapy for Castration-Resistant Prostate Cancer | 2.0 | 12 | Citations (PDF) |
| 184 | A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study | 27.4 | 117 | Citations (PDF) |
| 185 | The altered expression of MiR‐221/‐222 and MiR‐23b/‐27b is associated with the development of human castration resistant prostate cancer | 2.1 | 87 | Citations (PDF) |
| 186 | Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer | 25.2 | 1,441 | Citations (PDF) |
| 187 | Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile | 12.5 | 1,076 | Citations (PDF) |
| 188 | Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer | 4.0 | 48 | Citations (PDF) |
| 189 | The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature | 2.1 | 30 | Citations (PDF) |
| 190 | Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade | 3.2 | 5 | Citations (PDF) |
| 191 | Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer | 4.6 | 250 | Citations (PDF) |
| 192 | Immunotherapy for the treatment of prostate cancer | 70.7 | 94 | Citations (PDF) |
| 193 | Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality | 1.5 | 49 | Citations (PDF) |
| 194 | Single‐nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer | 3.2 | 39 | Citations (PDF) |
| 195 | Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy | 3.2 | 9 | Citations (PDF) |
| 196 | The genomic complexity of primary human prostate cancer | 37.9 | 1,173 | Citations (PDF) |
| 197 | Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer | 2.3 | 15 | Citations (PDF) |
| 198 | Elevated plasma tissue inhibitor of metalloproteinase‐1 levels predict decreased survival in castration‐resistant prostate cancer patients | 4.0 | 36 | Citations (PDF) |
| 199 | Risk of All-Cause and Prostate Cancer–Specific Mortality After Brachytherapy in Men With Small Prostate Size | 1.5 | 11 | Citations (PDF) |
| 200 | Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort | 6.8 | 21 | Citations (PDF) |
| 201 | Prostate Cancer Immunotherapy | 6.8 | 58 | Citations (PDF) |
| 202 | The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness | 1.5 | 30 | Citations (PDF) |
| 203 | Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer | 8.1 | 69 | Citations (PDF) |
| 204 | Activity of ketoconazole after taxane‐based chemotherapy in castration‐resistant prostate cancer | 3.2 | 25 | Citations (PDF) |
| 205 | Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer | 16.5 | 242 | Citations (PDF) |
| 206 | Comorbidity, body mass index, and age and the risk of nonprostate‐cancer‐specific mortality after a postradiation prostate‐specific antigen recurrence | 4.0 | 11 | Citations (PDF) |
| 207 | Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations | 1.5 | 17 | Citations (PDF) |
| 208 | Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group | 1.5 | 46 | Citations (PDF) |
| 209 | Molecular sampling of prostate cancer: a dilemma for predicting disease progression | 1.7 | 227 | Citations (PDF) |
| 210 | Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer | 3.8 | 113 | Citations (PDF) |
| 211 | Genome-wide Association Study of Prostate Cancer Mortality | 1.1 | 47 | Citations (PDF) |
| 212 | A Large Prospective Study of
SEP15
Genetic Variation, Interaction with Plasma Selenium Levels, and Prostate Cancer Risk and Survival | 1.5 | 82 | Citations (PDF) |
| 213 | Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy | 1.1 | 19 | Citations (PDF) |
| 214 | Changes In PSA Kinetics After DNA Vaccine Therapy–Not So Fast! | 16.9 | 4 | Citations (PDF) |
| 215 | Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population | 6.8 | 38 | Citations (PDF) |
| 216 | Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis | 3.2 | 84 | Citations (PDF) |
| 217 | Chemorad Nanoparticles: A Novel Multifunctional Nanoparticle Platform for Targeted Delivery of Concurrent Chemoradiation | 3.0 | 102 | Citations (PDF) |
| 218 | Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer | 34.5 | 5,310 | Citations (PDF) |
| 219 | Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer | 16.9 | 74 | Citations (PDF) |
| 220 | Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer | 6.8 | 78 | Citations (PDF) |
| 221 | Activity of Dutasteride Plus Ketoconazole in Castration-Refractory Prostate Cancer After Progression on Ketoconazole Alone | 2.3 | 18 | Citations (PDF) |
| 222 | Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study | 4.3 | 9 | Citations (PDF) |
| 223 | Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy | 4.0 | 128 | Citations (PDF) |
| 224 | Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death | 1.5 | 45 | Citations (PDF) |
| 225 | Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer | 33.6 | 854 | Citations (PDF) |
| 226 | Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research | 2.3 | 21 | Citations (PDF) |
| 227 | Androgen receptor mediates the expression of UDP‐glucuronosyltransferase 2 B15 and B17 genes | 2.1 | 73 | Citations (PDF) |
| 228 | Superparamagnetic Iron Oxide Nanoparticle–Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy | 3.1 | 312 | Citations (PDF) |
| 229 | Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer | 4.0 | 124 | Citations (PDF) |
| 230 | Active surveillance for early‐stage prostate cancer | 4.0 | 259 | Citations (PDF) |
| 231 | Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer | 4.0 | 37 | Citations (PDF) |
| 232 | Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer | 3.2 | 44 | Citations (PDF) |
| 233 | A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones | 3.2 | 71 | Citations (PDF) |
| 234 | Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time | 4.2 | 139 | Citations (PDF) |
| 235 | p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682) | 1.4 | 22 | Citations (PDF) |
| 236 | In Reply | 16.9 | 0 | Citations (PDF) |
| 237 | Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer | 16.9 | 103 | Citations (PDF) |
| 238 | Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort | 1.1 | 19 | Citations (PDF) |
| 239 | Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer | 4.6 | 300 | Citations (PDF) |
| 240 | Risk of Prostate Cancer Recurrence in Men Treated With Radiation Alone or in Conjunction With Combined or Less Than Combined Androgen Suppression Therapy | 16.9 | 59 | Citations (PDF) |
| 241 | Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer | 16.9 | 190 | Citations (PDF) |
| 242 | Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer | 16.5 | 638 | Citations (PDF) |
| 243 | In Reply | 16.9 | 1 | Citations (PDF) |
| 244 | Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions | 16.9 | 488 | Citations (PDF) |
| 245 | Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data | 4.7 | 13 | Citations (PDF) |
| 246 | Aspirin and Hormone Therapy for Prostate Cancer | 34.5 | 8 | Citations (PDF) |
| 247 | Prostate Cancer Risk and ESR1 TA, ESR2 CA Repeat Polymorphisms | 1.1 | 32 | Citations (PDF) |
| 248 | Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer | 16.9 | 311 | Citations (PDF) |
| 249 | Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma | 2.3 | 122 | Citations (PDF) |
| 250 | Bone Directed Therapies for Prostate Cancer | 4.2 | 10 | Citations (PDF) |
| 251 | Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer | 4.2 | 23 | Citations (PDF) |
| 252 | Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment | 4.2 | 381 | Citations (PDF) |
| 253 | Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference | 4.2 | 0 | Citations (PDF) |
| 254 | GENETIC DETERMINANTS OF PROSTATE CANCER RISK | 3.2 | 6 | Citations (PDF) |
| 255 | PROSTATE‐SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER: A DECISION‐ANALYTICAL PERSPECTIVE | 3.2 | 2 | Citations (PDF) |
| 256 | Quantum Dot−Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer | 8.7 | 1,004 | Citations (PDF) |
| 257 | Advances in the Treatment of Prostate Cancer | 18.7 | 31 | Citations (PDF) |
| 258 | Attempts at Gene Therapy in β-Thalassemic Mice | 4.0 | 3 | Citations (PDF) |
| 259 | Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone- Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480 | 2.3 | 41 | Citations (PDF) |
| 260 | Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes | 1.4 | 54 | Citations (PDF) |
| 261 | Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen | 1.8 | 37 | Citations (PDF) |
| 262 | Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy
in vivo | 7.5 | 1,679 | Citations (PDF) |
| 263 | Development of an Integrated Prostate Cancer Research Information System | 2.3 | 59 | Citations (PDF) |
| 264 | Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer | 4.0 | 43 | Citations (PDF) |
| 265 | Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer | 4.0 | 44 | Citations (PDF) |
| 266 | The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers | 2.8 | 33 | Citations (PDF) |
| 267 | Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy | 16.9 | 125 | Citations (PDF) |
| 268 | Carboplatin for Stage I Seminoma | 16.9 | 5 | Citations (PDF) |
| 269 | Efficacy of nilutamide as secondary hormonal therapy in androgen‐independent prostate cancer | 3.2 | 30 | Citations (PDF) |
| 270 | Decreased α-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death | 1.1 | 109 | Citations (PDF) |
| 271 | p63 regulates commitment to the prostate cell lineage | 7.5 | 137 | Citations (PDF) |
| 272 | Prediagnostic Plasma Vascular Endothelial Growth Factor Levels and Risk of Prostate Cancer | 1.1 | 16 | Citations (PDF) |
| 273 | Autoantibody Signatures in Prostate Cancer | 34.5 | 591 | Citations (PDF) |
| 274 | Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study | 1.4 | 89 | Citations (PDF) |
| 275 | Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era | 1.1 | 217 | Citations (PDF) |
| 276 | A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer | 6.8 | 75 | Citations (PDF) |
| 277 | 6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer | 16.5 | 729 | Citations (PDF) |
| 278 | Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer | 16.9 | 118 | Citations (PDF) |
| 279 | Genotyping and functional analysis of the D104N variant of human endostatin | 4.1 | 15 | Citations (PDF) |
| 280 | Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy | 4.0 | 129 | Citations (PDF) |
| 281 | Effect of finasteride on risk of prostate cancer: How little we really know | 3.0 | 13 | Citations (PDF) |
| 282 | Feasibility of Radical Prostatectomy After Neoadjuvant Chemohormonal Therapy for Patients With High Risk or Locally Advanced Prostate Cancer: Results of a Phase I/II Study | 4.2 | 85 | Citations (PDF) |
| 283 | FOURTH INTERNATIONAL CONFERENCE ON INNOVATIONS AND CHALLENGES IN PROSTATE CANCER: PREVENTION, DETECTION AND TREATMENT | 4.2 | 4 | Citations (PDF) |
| 284 | Plasma Levels of Heat Shock Protein 70 in Patients with Prostate Cancer: A Potential Biomarker for Prostate Cancer | 1.7 | 94 | Citations (PDF) |
| 285 | Absence of a Correlation of Androgen Receptor Gene CAG Repeat Length and Prostate Cancer Risk in an African-American Population | 1.7 | 33 | Citations (PDF) |
| 286 | Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer | 1.4 | 27 | Citations (PDF) |
| 287 | Racial Differences in Screening for Prostate Cancer in the Elderly | 8.1 | 102 | Citations (PDF) |
| 288 | Differentiating agents and the treatment of prostate cancer: vitamin D and peroxisome proliferator-activated receptor gamma ligands | 1.9 | 14 | Citations (PDF) |
| 289 | Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma | 4.0 | 10 | Citations (PDF) |
| 290 | Male Patients with Diagnoses of Both Breast Cancer and Prostate Cancer | 4.0 | 17 | Citations (PDF) |
| 291 | Third International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment | 4.2 | 5 | Citations (PDF) |
| 292 | Mutations in Ribonuclease L Gene Do NotOccur at a Greater Frequency in Patients with Familial Prostate Cancer Compared with Patients with Sporadic Prostate Cancer | 1.7 | 19 | Citations (PDF) |
| 293 | Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up | 1.4 | 25 | Citations (PDF) |
| 294 | Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update | 1.4 | 100 | Citations (PDF) |
| 295 | Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer | 16.9 | 661 | Citations (PDF) |
| 296 | Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663 | 16.9 | 349 | Citations (PDF) |
| 297 | Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Metastatic Prostate Cancer: A Nested Study Within CALGB 9583 | 16.9 | 55 | Citations (PDF) |
| 298 | Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model | 7.5 | 285 | Citations (PDF) |
| 299 | Chemotherapy for Teratoma With Malignant Transformation | 16.9 | 230 | Citations (PDF) |
| 300 | Time Course and Predictors of Symptoms After Primary Prostate Cancer Therapy | 16.9 | 201 | Citations (PDF) |
| 301 | Prevention of Prostate Cancer with Finasteride | 34.5 | 18 | Citations (PDF) |
| 302 | Title is missing! | 1.3 | 3 | Citations (PDF) |
| 303 | Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer | 1.3 | 6 | Citations (PDF) |
| 304 | A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients | 1.6 | 4 | Citations (PDF) |
| 305 | Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer | 4.0 | 635 | Citations (PDF) |
| 306 | ATAAA repeat upstream of glutathione S-transferase P1 and prostate cancer risk | 1.4 | 6 | Citations (PDF) |
| 307 | Overview consensus statement | 1.4 | 33 | Citations (PDF) |
| 308 | Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma | 4.0 | 12 | Citations (PDF) |
| 309 | Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer | 4.0 | 22 | Citations (PDF) |
| 310 | Selective aromatase inhibition for patients with androgen-independent prostate carcinoma | 4.0 | 52 | Citations (PDF) |
| 311 | Title is missing! | 2.5 | 25 | Citations (PDF) |
| 312 | Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer | 4.0 | 158 | Citations (PDF) |
| 313 | PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER | 4.2 | 1 | Citations (PDF) |
| 314 | Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer | 1.4 | 70 | Citations (PDF) |
| 315 | Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer | 16.9 | 185 | Citations (PDF) |
| 316 | Low bone mineral density in hormone-na�ve men with prostate carcinoma | 4.0 | 132 | Citations (PDF) |
| 317 | Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report | 1.9 | 63 | Citations (PDF) |
| 318 | Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer | 34.5 | 686 | Citations (PDF) |
| 319 | Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report | 1.9 | 4 | Citations (PDF) |
| 320 | Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer | 16.5 | 151 | Citations (PDF) |
| 321 | Vinorelbine and estramustine in androgen-independent metastatic prostate cancer | 4.0 | 35 | Citations (PDF) |
| 322 | Amplified in Breast Cancer‐1 Glutamine Repeat and Prostate Cancer Risk | 0.0 | 14 | Citations (PDF) |
| 323 | HRAS1 Proto-Oncogene Polymorphism and Prostate Cancer | 0.0 | 0 | Citations (PDF) |
| 324 | Utilizing Predictions of Early Prostate-Specific Antigen Failure to Optimize Patient Selection for Adjuvant Systemic Therapy Trials | 16.9 | 44 | Citations (PDF) |
| 325 | Racial Variation in Prostate Cancer Incidence and in Hormonal System Markers Among Male Health Professionals | 4.6 | 232 | Citations (PDF) |
| 326 | Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer | 4.6 | 339 | Citations (PDF) |
| 327 | Case 1-2000 | 34.5 | 10 | Citations (PDF) |
| 328 | Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma | 1.4 | 28 | Citations (PDF) |
| 329 | COMPARING PROSTATE SPECIFIC ANTIGEN OUTCOMES AFTER DIFFERENT TYPES OF RADIOTHERAPY MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE CANCER HIGHLIGHTS THE IMPORTANCE OF CONTROLLING FOR ESTABLISHED PROGNOSTIC FACTORS | 4.2 | 12 | Citations (PDF) |
| 330 | COMPARING PROSTATE SPECIFIC ANTIGEN OUTCOMES AFTER DIFFERENT TYPES OF RADIOTHERAPY MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE CANCER HIGHLIGHTS THE IMPORTANCE OF CONTROLLING FOR ESTABLISHED PROGNOSTIC FACTORS | 4.2 | 1 | Citations (PDF) |
| 331 | Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step? | 16.9 | 36 | Citations (PDF) |
| 332 | Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study | 16.9 | 863 | Citations (PDF) |
| 333 | Title is missing! | 2.5 | 55 | Citations (PDF) |
| 334 | Phase II Trial of the Antiestrogen Toremifene for Androgen-Independent Prostate Cancer | 0.0 | 1 | Citations (PDF) |
| 335 | A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma 1999, 86, 1329-1334 | | 6 | Citations (PDF) |
| 336 | CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians 1999, 39, 130-134 | | 64 | Citations (PDF) |
| 337 | Modification of BRCA1-Associated Breast Cancer Risk by the Polymorphic Androgen-Receptor CAG Repeat | 6.5 | 228 | Citations (PDF) |
| 338 | The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia | 1.4 | 120 | Citations (PDF) |
| 339 | Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer | 1.4 | 251 | Citations (PDF) |
| 340 | Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors | 1.4 | 108 | Citations (PDF) |
| 341 | PROGNOSTIC INDICATORS IN HORMONE REFRACTORY PROSTATE CANCER | 2.0 | 26 | Citations (PDF) |
| 342 | PLASMA LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ARE INCREASED IN PATIENTS WITH METASTATIC PROSTATE CANCER | 4.2 | 1 | Citations (PDF) |
| 343 | HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182 | 4.2 | 2 | Citations (PDF) |
| 344 | LAPAROSCOPIC RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TESTICULAR TUMORS (NSGCT) | 4.2 | 0 | Citations (PDF) |
| 345 | The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer | 7.0 | 21 | Citations (PDF) |
| 346 | MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS | 4.2 | 226 | Citations (PDF) |
| 347 | Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy | 1.4 | 13 | Citations (PDF) |
| 348 | MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER | 4.2 | 12 | Citations (PDF) |
| 349 | The CAG repeat within the androgen receptor gene and its relationship to prostate cancer | 7.5 | 779 | Citations (PDF) |
| 350 | Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate | 1.4 | 85 | Citations (PDF) |
| 351 | Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma | 1.4 | 64 | Citations (PDF) |
| 352 | Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma | 1.4 | 9 | Citations (PDF) |
| 353 | Regulation of S100P expression by androgen 1996, 29, 350-355 | | 72 | Citations (PDF) |
| 354 | Nonpalpable Intratesticular Masses Detected Sonographically | 4.2 | 79 | Citations (PDF) |
| 355 | Nonpalpable Intratesticular Masses Detected Sonographically | 4.2 | 1 | Citations (PDF) |
| 356 | Rate of relapse following treatment for localized prostate cancer: A critical analysis of retrospective reports | 1.5 | 21 | Citations (PDF) |
| 357 | Laparoscopic Retroperitoneal Lymphadenectomy: Multi-Institutional Analysis | 4.2 | 77 | Citations (PDF) |
| 358 | Retroperitoneal Lymphocele Formation after Selective Laparoscopic Retroperitoneal Lymph Node Sampling | 4.2 | 4 | Citations (PDF) |
| 359 | The Prostate Specific Antigen: Its Use as a Tumor Marker for Prostate Cancer | 2.2 | 7 | Citations (PDF) |
| 360 | Meningeal carcinomatosis from transitional cell carcinoma of the bladder | 4.0 | 31 | Citations (PDF) |
| 361 | Synchronous Adenocarcinoma and Transitional Cell Carcinoma of the Bladder Associated with Augmentation: Case Report And Review of the Literature | 4.2 | 52 | Citations (PDF) |
| 362 | 14-Day Continuous Infusion of Mitoxantrone in Hormone-Refractory Metastatic Adenocarcinoma of the Prostate | 1.3 | 25 | Citations (PDF) |
| 363 | Long-Term Followup of 150 Patients with Testicular Cancer Treated at a Single Institution | 4.2 | 6 | Citations (PDF) |
| 364 | Chemotherapy for Muscle-infiltrating Bladder Cancer | 2.2 | 13 | Citations (PDF) |
| 365 | Hormonal perturbations in patients with testicular cancer treated with cisplatin | 4.0 | 22 | Citations (PDF) |
| 366 | Chemotherapy for Metastatic Bladder Cancer | 2.2 | 6 | Citations (PDF) |
| 367 | Bladder cancer | 1.9 | 9 | Citations (PDF) |
| 368 | Histologic Demonstration of Intradermal Spirochetes in a Patient with Lyme Disease | 0.9 | 5 | Citations (PDF) |
| 369 | Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays | 0.7 | 17 | Citations (PDF) |
